Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib, Chidamide, and Sintilimab in MSS/pMMR Metastatic Colorectal Cancer
NCT06685276Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC). Started Aug 2024; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06685276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685276.